SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets closed

Sanofi (SNY)


NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
40.40+0.63 (+1.58%)
At close: 4:02 PM EST
People also watch:
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close39.77
Open40.31
Bid40.34 x 200
Ask40.46 x 100
Day's Range40.17 - 40.54
52 Week Range36.81 - 44.50
Volume1,438,696
Avg. Volume2,596,375
Market Cap104.26B
Beta0.83
PE Ratio (TTM)23.48
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.66 (4.09%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Is Total SA (ADR) (TOT) A Better Stock Than Its Peers?
    Insider Monkey9 hours ago

    Is Total SA (ADR) (TOT) A Better Stock Than Its Peers?

    Like everyone else, successful investors make mistakes. Some of their top consensus picks, such as Valeant and SunEdison, have not done well during the last 12 months due to various reasons. Nevertheless, the data show successful investors’ consensus picks have done well on average. The top 30 mid-cap stocks (market caps between $1 billion and […]

  • Inovio Pharmaceuticals, Inc.'s Biggest Win in 2016
    Motley Fool2 days ago

    Inovio Pharmaceuticals, Inc.'s Biggest Win in 2016

    Inovio had a setback with its cervical dysplasia vaccine program, but the biotech also had a huge win this year.

  • EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA
    Insider Monkey2 days ago

    EMA Reviews Regeneron Pharmaceuticals Inc (REGN), Sanofi SA (ADR) (SNY) Dupixent MAA

    The European Medicines Agency (EMA) has recently accepted to review the Marketing Authorization Application (MAA) of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA (ADR) (NYSE:SNY) for Dupixent (dupilumab) as a treatment for adult moderate-to-severe atopic dermatitis (AD) patients who are systemic therapy candidates. Dupixent is an investigational biologic therapy that inhibits the signaling of two […]